TABLE 1.
Crohn’s Disease | N = 15 |
---|---|
Steroids % (n) | |
Prednisone | 26.7% (4) |
Budesonide | 6.7% (1) |
Biologics | |
Vedolizumab | 20% (3) |
Certolizumab | 13.3% (2) |
Adalimumab | 6.7% (1) |
Infliximab | 6.7% (1) |
Ustekinumab | 6.7% (1) |
Cyclosporine | 6.7% (1) |
Mesalamine | |
Oral 5-ASA | 13.3% (2) |
Rectal 5-ASA | 6.7% (1) |
Immunomodulators | |
Azathioprine | 13.3% (2) |
Methotrexate | 13.3% (2) |
Ulcerative Colitis | N = 35 |
Steroids | |
Prednisone | 48.6% (17) |
Budesonide | 5.7% (2) |
Rectal Corticosteroids | 8.6% (3) |
Biologics | |
Adalimumab | 8.6% (3) |
Vedolizumab | 22.9% (8) |
Infliximab | 17.1% (6) |
Tofacitanib | 2.9% (1) |
Cyclosporine | 2.9% (1) |
Mesalamine | |
Rectal 5-ASA | 11.4% (4) |
Oral 5-ASA | 57% (20) |
Immunomodulator | |
Methotrexate | 2.9% (1) |